Erytech Pharma SA

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

—

Shrs. gr., 5y

-22.30%

Rev. gr., 5y

12.50%

Revenues

Net income

-228k

L-99.58%

CFO

-32m

L-44.05%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.

URL

https://erytech.com/

IPO date

May 07, 2013

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT